Drug guides / Nonhormonal prescriptions
Veozah vs Lynkuet: monitoring and prescription differences
At a glance
Veozah (fezolinetant) and Lynkuet (elinzanetant) are different nonhormonal medicines for menopausal hot flashes. Their liver-testing schedules and safety considerations differ. Comparing their labels can clarify the practical choice, but these sources do not establish a head-to-head efficacy winner. Veozah source · Lynkuet source
Product facts behind the comparison
| Product | Ingredient | Form | Labeled role |
|---|---|---|---|
| Veozah | fezolinetant | Oral tablet | Menopausal moderate-to-severe hot flashes Veozah source |
| Lynkuet | elinzanetant | Oral capsule | Menopausal moderate-to-severe hot flashes Lynkuet source |
Routine and safety questions
- Veozah: 45 mg once daily. Liver injury boxed warning; baseline tests, monthly for 3 months, then months 6 and 9. Veozah source
- Lynkuet: Two 60 mg capsules once daily at bedtime; interaction adjustments may apply. Liver tests before treatment and at 3 months; daytime impairment, pregnancy and seizure warnings. Lynkuet source
These schedules summarize label information for comparison, not instructions to start, stop or change a prescription. Contraindications, interactions and other warnings are not exhaustively listed here. Follow the actual prescription and read the linked full label.
What changes in the day-to-day treatment plan?
| Decision point | Veozah | Lynkuet |
|---|---|---|
| Labeled routine | 45 mg once daily. | 120 mg as two 60 mg capsules at bedtime; interacting medicines can require a different plan. |
| Liver bloodwork | Before treatment, monthly during the first three months, then at months 6 and 9. | Before treatment and at month 3; additional assessment may be needed. |
| A difference to raise at the visit | The label has a boxed warning for liver injury and contraindicates CYP1A2 inhibitors. | The label warns about daytime impairment and CNS effects; discuss driving and other sedating medicines. |
| What to put in the budget | The prescribed tablet supply plus the ordered laboratory work. | The prescribed capsule supply plus the ordered laboratory work. |
These are selected label distinctions, not a complete safety screen or an efficacy ranking. Symptoms or abnormal results can change monitoring. Ask the prescriber to review the full medicine list before either option enters a price comparison.
How to use this comparison
Take two separate pharmacy quotes to the discussion and request a lab-cost estimate for each proposed plan. A tablet count is not a capsule count: ask the pharmacy to state days supplied. Record whether laboratory fees are billed through medical coverage and prescription fees through pharmacy coverage. A low advertised refill price cannot establish the combined cost. If the clinician rules one option out, remove it from the financial comparison rather than keeping it as a misleading cheaper alternative.
Questions about this decision
Does nonhormonal mean no monitoring?
No. Both labels include liver assessment. Use each product’s own schedule rather than applying one schedule to the other.
Can I compare trial percentages as a ranking?
This guide does not make that ranking. Separate trials can differ in participants, endpoints and follow-up.
What should my insurer quote?
The exact product, strength, quantity and days supplied, plus any authorization requirement.
Is the newer product automatically a better fit?
Approval date alone does not settle suitability. Ask how the warnings, other medicines and daily routine apply to you.
What this guide does not establish
No head-to-head superiority, automatic substitution, pharmacy stock, personalized insurance coverage or guaranteed savings is established here. A label source supports the specific product facts cited; it does not endorse this website or validate a calculator result.
Access and savings: two programs, not a $5 price contest
The manufacturers advertise conditional commercial minimums of $30 for Veozah refills and $25 for Lynkuet. Those headlines have different program rules and do not establish a matched personal price. Veozah also advertises an eligible first-fill offer; Lynkuet lists a separate BlinkRx route. Astellas: Veozah savings and eligibility. Bayer: Lynkuet cost and savings.
Veozah’s label calls for baseline liver tests, monthly checks for the first three months, and checks at months six and nine. Lynkuet’s label calls for baseline and three-month liver testing and includes daytime-impairment warnings. Price the actual clinician-ordered care rather than assuming identical monitoring expenses. Veozah prescribing information. Lynkuet prescribing information.
Use Veozah’s cost guide and Lynkuet’s combined cost and savings guide for dated restrictions. Government-insurance patients should use the plan and appropriate assistance routes, not assume the commercial cards apply.
Related decisions
- Brisdelle vs Veozah: different nonhormonal approaches
- Veozah cost: include the liver-monitoring budget
- Lynkuet cost: capsules, monitoring and access
Sources and verification scope
- Veozah — label or manufacturer information
Used for: Highlights; sections 1, 2 and 5. Selected facts checked 2026-09-15. No pharmacy stock or personal coverage verification. - Lynkuet — label or manufacturer information
Used for: August 2026 label; sections 1, 2 and 5. Selected facts checked 2026-09-15. No pharmacy stock or personal coverage verification.
Editorial synthesis connects the cited facts to practical questions. Sources were checked for the selected facts, not audited for every possible warning. Current pharmacy quotes and independent clinical review are still outstanding.
Machine-readable answer and evidence record (JSON)
Related comparison: Veozah vs gabapentin for hot flashes: approval, monitoring and cost questions.